zacks.com / Page 9

NVIDIA's historic rise faces fresh rivalry as Micron and Palantir post explosive AI-driven growth. Could MU or PLTR mirror NVDA's success?

RIVN posts a narrower-than-expected Q4 loss and beats revenue estimates, but vehicle deliveries, margins and cash flow weaken; 2026 shipments increase year over year.

SPNT gears up for Q4 results with revenues and EPS expected to surge, but our model signals no clear earnings beat.

Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudson's mandate and names Belen Garijo as successor amid investor skepticism.

WAT tops Q4 estimates as revenues rise 7% Y/Y, with strong Pharma and Europe growth, and upbeat 2026 sales and earnings outlook.

IPGP beat Q4 estimates as revenues rise 17% Y/Y, driven by industrial demand and growth products, sending shares sharply higher.

Woodward (WWD) could produce exceptional returns because of its solid growth attributes.

DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.

Stantec (STN) could produce exceptional returns because of its solid growth attributes.

New Gold (NGD) possesses solid growth attributes, which could help it handily outperform the market.